Appetite suppressants as adjuncts in the treatment of obesity

Journal of Family Practice

Volumn 42, Issue 3, 1996, Pages 287-292

  Elks, Martha L ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

anorectic agents; appetite depressants; diabetes; hyperlipidemia; Obesity

Indexed keywords

AMFEPRAMONE; AMPHETAMINE DERIVATIVE; ANOREXIGENIC AGENT; FENFLURAMINE; FLUOXETINE; MAZINDOL; NON PRESCRIPTION DRUG; PHENTERMINE; PHENTERMINE RESIN; PHENYLPROPANOLAMINE; PLACEBO;

ADJUVANT THERAPY; ANIMAL MODEL; ANXIETY; CARDIOTOXICITY; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DRUG ABUSE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; NEUROTOXICITY; NONHUMAN; OBESITY; PATIENT SELECTION; PRACTICE GUIDELINE; REVIEW; WEIGHT REDUCTION;

APPETITE DEPRESSANTS; COMBINED MODALITY THERAPY; HUMANS; OBESITY; PATIENT SELECTION;

EID: 0029917519     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Bray GA. Obesity: basic considerations and clinical approaches. Dis Mon 1989; 18:449-540.
2. Van Italie TB. Health implications of overweight and obesity in the United States. Ann Intern Med 1985; 103.983-8.
3. Kuczmarski RJ. Prevalence of overweight and weight gain in the United States. Am J Clin Nutr 1992; 55:(suppl 1)495S-502S.
4. Kucsmarski BJ, Flegal KM, Campbell SM, et al. Increasing prevalence of overweight among US adults. The NHNES 1960-91. JAMA 1994; 272:205-11.
5. Serdula MK, Mokdad AH, Pamuk ER, Williamson DF, Byers T. Effects of question order on estimates of the prevalence of attempted weight Loss. Am J Epidemiol 1995; 142:64-7.
6. Goodrick GK, Foreyt JP. Why treatments for obesity don't last. J Am Diet Assoc 1991; 91:1243-7.
7. Goldstein DJ, Potvin JH. Long-term weight loss: the effect of pharmacologic agents. Am J Clin Nutr 1994; 60:647-57.
8. Wilson MA. Southwestern Internal Medicine Conference: treatment of obesity Am J Med Sci 1990; 299:62-8.
9. Atkinson RL, Hubbard VS. Report on the NIH workshop on pharmacologic treatment of obesity. Am J Clin Nutr 1994; 60:153-6.
10. Bray GA. Barriers to the treatment of obesity. Ann Intern Med 1991; 115:152-3.
11. Weintraub M, Bray GA. Drug treatment of obesity. Med Clin North Am 1989; 73:237-49.
12. Bray GA. Drug treatment of obesity. Am J Clin Nutr 1992; 55: 538S-544S.
13. Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 1993; 119:707-13
14. Stunkard A. Anoretic agents lower a body weight set point. Life Sci 1982; 30:2043-55.
15. Weintraub M. Long-term weight control: the NHLBI funded multimodel intervention study. Clin Pharmacol Ther 1992; 51:581-5.
16. Weintraub M, Sundaresan PR, Madan M, et al. Long-term weight control study I (weeks 1 to 34). Clin Pharmacol Ther 1992; 51: 586-94.
17. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study II (weeks 34 to 104). Clin Pharmacol Ther 1992; 51:595-601
18. Weintraub M, Sundaresan PR, Schuster B, Moscucci M, Stein EC. Long-term weight control study III (weeks 104 to 156). Clin Pharmacol Ther 1992, 51:602-7.
19. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study IV (weeks 156 to 190). Clin Pharmacol Ther 1992; 51:608-14.
20. Weintraub M, Sundaresan PR, Schuster B, Averbuch M, Stein EC, Byrne L. Long-term weight control study V (weeks 190 to 210). Clin Pharmacol Ther 1992; 51:615-8.
21. Weintraub M, Sundaresan PR, Cox C. Long-term weight control study VI. Clin Pharmacol Ther 1992; 51:619-33.
22. Weintraub M, Sundaresan PR, Schuster B. Long-term weight control study VII (weeks 0 to 210). scrum lipid changes. Clin Pharmacol Ther 1992; 51:634-41.
23. Weintraub M. Long-term weight control study: conclusions. Clin Pharmacal Ther 1992; 51:642-6
24. Scoville BA. Review of amphetamine-like drugs by the Food and Drug Administration: clinical data and value judgments. In: Bray GA, ed. Obesity in perspective, Bethesda, Md: National Institutes of Health, 1975.441-3. DHEW publication No.(NIH) 75-708.
25. Weintraub M. Phenylpropanolamine as a anorexiant agent in weight control: a review of published and unpublished studies. In: Morgan JP, Kagan DV, Brody JS, eds. Phenylpropanolamine. New York, NY: Praeger Scientific, 1985:53-79.
26. Silverstone JT, Solomon T. The long-term management of obesity in general practice. Br J Clin Pract 1965; 19:395-8.
27. McKay RHG. Long-term use of diethylpropion in obesity. Curr Med Res Opin 1973; 1:489-93.
28. Enzi G, Baritussio A, Marchiori E, Crepaldi G. Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity. J Int Med Res 1976, 4:305-17.
29. Judson KD. The anoretic and hypotensive effect of fenfluramine in obesity. J R Coll Gen Pract 1977; 27:497-501.
30. Stunkard AJ, Craighead LW, O'Brien RM. Controlled trial of behavior therapy, pharmacotherapy, and their combination in the treatment of obesity. Lancet 1980; 2:1045-7.
31. Craighead LW, Stunkard AJ, O'Brien RM Behavior therapy and pharmacotherapy for obesity. Arch Gen Psychiatry 1981; 38:763-8.
32. Douglas JG, Gough J, Preston PG, et al. Long-term treatment with fenfluramine in obese subject. Int J Clin Pharmacol Res 1985; 4:247-53.
33. Finer N, Craddock D, Lavielle R, Keen H Prolonged weight loss with dexfenfluramine treatment in obese patients. Diabetes Metab 1987; 13:598-602.
34. Finer N, Craddock D, Lavielle R, Keen H. Dextrofenfluramine in the treatment of refractory obesity. Curr Ther Res 1985; 38:847-54.
35. Steel JM, Munro JF, Duncan LJP. A comparative trial of different regimens of fenfluramine and pheritermine in obesity Practitioner 1973; 211:232-6.
36. Goldstein DJ, Rampey AH, Dornseif BE, Levine LR, Potvin JH, Fludzinski LA. Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obes Res 1993;1:92-8.
37. Fluoxetine and other drugs for treatment of obesity. Med Lett 1994; 36:107-8.
38. Turner P. Dexfenfluraminc: its place in weight control. Drugs 1990; 39:53-62.
39. Tauber-Lassen E, Damsbo P, Henriksen JE, Palmvig B, Beck-Nielsen H. Improvement of glycemic control and weight loss in type 2 (NIDDM) diabetics after one year of dexfenfluramine treatment. Diabetologica 1990; 33:A124.
40. Chiasson J-L, Lau DCW, Leiter LA, Tildeslcy HD, Birmingham CL, Ekoe JM. Fluoxetine has potential in obese NIDDM-multicenter Canadian trial. Diabetes 1989; 38:154A.
41. Willey KA, Molyneaux LM, Overland JE, Yue DK. The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes. Diabetic Med 1992; 9:341-3.
42. Stewart GO, Steing GR. Dexrenfluramine in type II diabetes: effects on weight and diabetes control. Med J Aust 1993; 158:167-9.
43. Gray DS, Fujioka K, Devine W, Bray GA. Fluoxetine treatment of the obese diabetic. Int J Obes 1992; 16:193-8.
44. Meinders AE, Piji H. Very low calorie diets and recently developed anti-obesity drugs for treating overweight non-insulin dependent diabetics. Int J Obes 1992; 16:535-46.
45. Watts NB, Spanheimer RG, DiGirolomo M, Rebhard SS, et al. Prediction of glucose response to weight loss in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 1990, 150. 803-6.
46. Goff DC, Scheklle RB, Moye LA, Katan MB, Gotto AM, Stamler J. Does body fatness modify the effect of dietary cholesterol on serum cholesterol: results from the Chicago Western Electric Study. Am J Epidemiol 1993, 137:171-7.
47. Calles-Escandon J, Horton ES. The thermogenic role of exercise in the treatment of morbid obesity: a critical evaluation. Am J Clin Nutr 1991; 55:533S-537S.
48. Wing RR. Behavioral treatment of severe obesity. Am J Clin Nutr 1992; 55:545S-551S.
49. Astrup A, Buemann B, Christensen J,Toubro S, Thorbek G, Victor OJ, Quaade F. The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women. Metabolism 1992; 41:686-8.
50. Kral JG. Overview of surgical techniques for treating obesity. Am J Clin Nutr 1992; 55:552S-555S
51. Physicians' desk reference. Montvale, NJ: Medical Economics, 1995.
52. Griffiths RR, Brady JV, Bradford LD. Predicting the abuse liability of drugs with animal drug self-administration procedures: psychomotor stimulants and hallucinogens. Adv Biol Pharmacol 1979, 2:163-208.
53. Phenylpropanolamine for weight reduction. Med Lett 1984; 26. 55-6.
54. Bale JF, Fountain T, Shaddy R. Phenylpropanolamine-assoctited CNS complications in children and adults. Am J Dis Child 1984; 138:683-5.
55. Blackburn GL, Morgan JP, Lavin PT, Noble R, Funderburk FR, Istfan N. Determinants of the pressor effect of phenylpropano-Jamine in healthy subjects. JAMA 1989; 26:3267-73.
56. Woo OF, Benowitz NL, Bialy FW, Wengert JW. Atrioventricular conduction block caused by phenylpropanolamine. JAMA 1985; 253:2646-7.
57. Grundy SM, Barnett JP. Metabolic and health complications of obesity. Dis Mon 1990; 36.611-731.